Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends

MrDecoder · 2026-03-27T10:13:49+00:00

This essay highlights the benefits of investing in AbbVie for dividend income, detailing its significant dividend yield, reliable payouts, and growth potential, alongside a calculation for the number of shares needed to generate $10,000 annually.

MrDecoder

2026-03-27 10:13:49

Abstract generation in progress

It’s smart to seek dividend income from your investments because it can be used to help pay living expenses or to buy more stock. A solid dividend-paying stock to consider is pharmaceutical company AbbVie (ABBV +1.91%), which was spun off from Abbott Laboratories in 2013. The stock recently sported a 3.38% dividend yield, far above the average yield of 1.1% for stocks in the S&P 500.

If you’re looking for, say, $10,000 in annual dividend income, how many shares of AbbVie do you need to buy?

Image source: Getty Images.

Well, start by noting that the company’s last quarterly dividend payment was $1.73 per share. The yearly run rate, then, is $6.92 per share. So divide $10,000 by $6.92, and you’ll get 1,445 – the number of shares you’d need. With the stock recently trading around $205 per share (as of March 24), those 1,445 shares would cost you a hefty $296,225. (Fortunately, you can always buy fewer than 1,445 shares!)

Expand

NYSE: ABBV

AbbVie

Today’s Change

(1.91%) $3.96

Current Price

$211.14

Key Data Points

Market Cap

$373B

Day’s Range

$205.83 - $211.42

52wk Range

$164.39 - $244.81

Volume

180K

Avg Vol

7.2M

Gross Margin

70.12%

Dividend Yield

3.15%

One reason to consider investing in AbbVie is that it’s a rather reliable dividend payer – and dividend grower. Since 2013, it has upped its payout by more than 330%. Better still, when you combine its history with that of Abbott Labs, you’ll see that it has increased its payout annually for more than 25 years. So the $10,000 (or other sum) that you collect in dividends this year could be much more after a few years.

The dividend is not the only reason to consider AbbVie. It’s a strong grower in general, with its stock averaging annual gains of 16.2% over the past decade. Its 2025 revenue was up 8.6% over the year before – despite its having lost patent protection for its blockbuster drug, Humira. Its pipeline of 90-plus drugs in development is promising, too.

AbbVie’s stock is reasonably priced, with a recent forward-looking price-to-earnings (P/E) ratio of 14, a bit above the five-year average of 13.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.